Barnes P J, Ind P W, Dollery C T
Thorax. 1981 May;36(5):378-81. doi: 10.1136/thx.36.5.378.
Prazosin, a potent and selective alpha-adrenergic antagonist, was given by inhalation to nine asthmatic subjects aged 25-48 years (six with positive skin tests). Prazosin 0.5 mg, salbutamol 1 mg, or placebo were given by nebuliser in randomised double-blind fashion on separate days. Although all subjects showed a significant increase in FEV1, vital capacity, and maximum expiratory flow at 70% of total lung capacity after salbutamol, there was no significant difference between prazosin and placebo. This suggests that alpha-adrenergic receptors are not important in the control of bronchial tone in asthma. The weak bronchodilatation ascribed to alpha-antagonists in previous studies could be explained by other pharmacological actions of the drugs used.
哌唑嗪是一种强效且具有选择性的α-肾上腺素能拮抗剂,对9名年龄在25至48岁的哮喘患者(6名皮肤试验呈阳性)进行了吸入给药。分别在不同日期以随机双盲方式通过雾化器给予0.5毫克哌唑嗪、1毫克沙丁胺醇或安慰剂。尽管所有受试者在使用沙丁胺醇后第1秒用力呼气量(FEV1)、肺活量和肺总量70%时的最大呼气流量均显著增加,但哌唑嗪与安慰剂之间无显著差异。这表明α-肾上腺素能受体在哮喘患者支气管张力的控制中并不重要。先前研究中归因于α-拮抗剂的微弱支气管扩张作用可能由所用药物的其他药理作用来解释。